Evidence map›Paper›PMID 41667636›Full record

ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2026

Prevention of late-life depression: a framework and prospectus for research.

Olivia I Okereke

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Olivia I OkerekeDepartment of Psychiatry, Mass General Brigham, Boston, MA, USA. olivia.okereke@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-9523-2693

Funding

VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaLR01MH091448 · NIMH · BRIGHAM AND WOMEN'S HOSPITAL · PI OKEREKE, OLIVIA IFEOMA · 2010 to 2019
$6.5M
VITAL-DEP (VITamin D and OmegA 3 TriaL-Depression Endpoint Prevention)R56MH091448 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI OKEREKE, OLIVIA IFEOMA · 2022 to 2022
$1.3M
Patient-Centered Outcomes Research Institute (PCORI) HA-2022C3-30600U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) R01MH091448U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) R56MH091448
6 · The paper itself

Abstract

Depression is a leading cause of disease burden, disability, and distress for millions of older adults. Therefore, prevention of late-life depression (LLD) is a research and public health priority. Much of the research on depression prevention has been guided by the central framework of prevention of mental disorders that was developed by the National Academies of Medicine (NAM). This framework features three modes of prevention, centered on the group or people at risk: 1) indicated prevention, which focuses on those who have symptoms but are below the threshold of clinical disease; 2) selective prevention, which focuses on persons at higher risk to develop a disease because of having key risk factors; 3) universal prevention, which focuses on the population as a whole, regardless of risk factors or risk status. This perspective will provide illustrative examples of all three NAM modes of prevention, including one example from the author's work that simultaneously addressed indicated, selective, and universal prevention of late-life depression in the VITamin D and OmegA-3 TriaL-Depression Endpoint Prevention (VITAL-DEP) study. This paper will also discuss next steps in research to advance LLD prevention, with a view toward ensuring that all older adults can benefit from the increasing range of prevention options available.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.